Effect of evolocumab or ezetimibe added to moderate-or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 …
JG Robinson, BS Nedergaard, WJ Rogers, J Fialkow… - Jama, 2014 - jamanetwork.com
Importance In phase 2 studies, evolocumab, a fully human monoclonal antibody to PCSK9,
reduced LDL-C levels in patients receiving statin therapy. Objective To evaluate the efficacy …
reduced LDL-C levels in patients receiving statin therapy. Objective To evaluate the efficacy …
Effect of evolocumab or ezetimibe added to moderate-Or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: The LAPLACE-2 …
JG Robinson, BS Nedergaard, WJ Rogers, J Fialkow… - JAMA, 2014 - research.rug.nl
IMPORTANCE: In phase 2 studies, evolocumab, a fully human monoclonal antibody to
PCSK9, reduced LDL-C levels in patients receiving statin therapy. OBJECTIVE: To evaluate …
PCSK9, reduced LDL-C levels in patients receiving statin therapy. OBJECTIVE: To evaluate …
Effect of evolocumab or ezetimibe added to moderate-or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 …
J Robinson, B Nedergaard, W Rogers, J Fialkow… - JAMA, 2014 - arpi.unipi.it
IMPORTANCE: In phase 2 studies, evolocumab, a fully human monoclonal antibody to
PCSK9, reduced LDL-C levels in patients receiving statin therapy. OBJECTIVE: To evaluate …
PCSK9, reduced LDL-C levels in patients receiving statin therapy. OBJECTIVE: To evaluate …
Effect of evolocumab or ezetimibe added to moderate-or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 …
JG Robinson, BS Nedergaard, WJ Rogers, J Fialkow… - JAMA, 2014 - europepmc.org
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C
lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial …
lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial …
[引用][C] Effect of Evolocumab or Ezetimibe Added to Moderate-or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia
JG Robinson, BS Nedergaard, WJ Rogers, J Fialkow… - JAMA, 2014 - cir.nii.ac.jp
Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on
LDL-C Lowering in Patients With Hypercholesterolemia | CiNii Research CiNii 国立情報学研究所 …
LDL-C Lowering in Patients With Hypercholesterolemia | CiNii Research CiNii 国立情報学研究所 …
Effect of Evolocumab or Ezetimibe Added to Moderate-or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia The LAPLACE-2 …
JG Robinson, BS Nedergaard… - JAMA: Journal of …, 2014 - search.ebscohost.com
IMPORTANCE In phase 2 studies, evolocumab, a fully human monoclonal antibody to
PCSK9 reduced LDL-C levels in patients receiving statin therapy. OBJECTIVE To evaluate …
PCSK9 reduced LDL-C levels in patients receiving statin therapy. OBJECTIVE To evaluate …
[PDF][PDF] Effect of Evolocumab or Ezetimibe Added to Moderate-or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia The …
JG Robinson, BS Nedergaard, WJ Rogers, J Fialkow… - JAMA, 2014 - acc.org
Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on
LDL-C Lowering in Patients With Hyperch Page 1 Copyright 2014 American Medical Association …
LDL-C Lowering in Patients With Hyperch Page 1 Copyright 2014 American Medical Association …
Effect of evolocumab or ezetimibe added to moderate-or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 …
J Robinson, B Nedergaard, W Rogers, J Fialkow… - JAMA, 2014 - sfera.unife.it
IMPORTANCE: In phase 2 studies, evolocumab, a fully human monoclonal antibody to
PCSK9, reduced LDL-C levels in patients receiving statin therapy. OBJECTIVE: To evaluate …
PCSK9, reduced LDL-C levels in patients receiving statin therapy. OBJECTIVE: To evaluate …
[引用][C] Effect of Evolocumab or Ezetimibe Added to Moderate-or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia: The …
JG Robinson, BS Nedergaard… - JAMA: the journal of the …, 2014 - dialnet.unirioja.es
Importance In phase 2 studies, evolocumab, a fully human monoclonal antibody to PCSK9,
reduced LDL-C levels in patients receiving statin therapy. Objective To evaluate the efficacy …
reduced LDL-C levels in patients receiving statin therapy. Objective To evaluate the efficacy …
[PDF][PDF] Effect of Evolocumab or Ezetimibe Added to Moderate-or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia The …
JG Robinson, BS Nedergaard, WJ Rogers, J Fialkow… - JAMA, 2014 - researchgate.net
Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on
LDL-C Lowering in Patients With Hyperch Page 1 Copyright 2014 American Medical Association …
LDL-C Lowering in Patients With Hyperch Page 1 Copyright 2014 American Medical Association …